Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4

Clinical Cancer Research

Volumn 12, Issue 12, 2006, Pages 3792-3802

  Yang, Weilian ^a   Barth, Rolf F ^a   Wu, Gong ^a   Kawabata, Shinji ^a   Sferra, Thomas J ^a   Bandyopadhyaya, Achintya K ^a   Tjarks, Werner ^a   Ferketich, Amy K ^a   Moeschberger, Melvin L ^a   Binns, Peter J ^b   Riley, Kent J ^b   Coderre, Jeffrey A ^c   Ciesielski, Michael J ^d   Fenstermaker, Robert A ^d   Wikstrand, Carol J ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BORONOPHENYLALANINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; HYDRAZIDE DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L8A4; N (K MALEIMIDOUNDECANOIC ACID)HYDRAZIDE; N SUCCINIMIDYL 3 (2 PYRIDYLDITHIO)PROPIONIC ACID; POLYAMIDOAMINE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RESPONSE; GENETIC TRANSFECTION; GLIOMA; HISTOPATHOLOGY; KAPLAN MEIER METHOD; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; GLIOMA; HUMANS; INJECTIONS; IODINE RADIOISOTOPES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 33745711777     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0141     Document Type: Article

References (68)

1. Barth RF, Coderre JA, Vicente MG, et al. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 2005;11:3987-4002.
2. Coderre JA, Turcotte JC, Riley KJ, et al. Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat 2003;2:355-75.
3. Zamenhof RG, Coderre JA, Rivard MJ, et al. Eleventh World Congress on Neutron Capture Therapy. Appl Radiat Isot 2004;61:731-1130.
4. Frederick L, Wang XY, Eley G, et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
5. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2003;2:783-7.
6. Wikstrand CJ, Cole VR, Crotty LE, et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 2002;50:639-52.
7. Pedersen MW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy. Ann Oncol 2001;12:745-60.
8. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1-13S.
9. Capala J, Barth RF, Bendayan M, et al. Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjug Chem 1996;7:7-15.
10. Yang W, Barth RF, Adams DM, et al. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res 1997;57:4333-9.
11. Barth RF, Yang W, Adams DM, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res 2002;62:3159-66.
12. Yang W, Barth RF, Adams DM, et al. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res 2002;62:6552-8.
13. Yang W, Barth RF, Wu G, et al. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl Radiat Isot 2004;61:981-5.
14. Barth RF, Wu G, Yang W, et al. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat Isot 2004;61:899-903.
15. Wu G, Barth RF, Yang W, et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug Chem 2004;15:185-94.
16. Faillot T, Magdelenat H, Mady E, et al. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 1996;39:478-83.
17. Jørgensen PE, Poulsen SS, Nexø E. Distribution of i.v. administered epidermal growth factor in the rat. Regul Pept 1988;23:161-9.
18. 131I-labelled epidermal growth factor in the pig visualized by dynamic scintigraphy. J Endocrinol 1995;144:5-12.
19. Yang W, Barth RF, Leveille R, et al. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent. J Neurooncol 2001;55:19-28.
20. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
21. Liu L, Backlund LM, Nilsson BR, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005;83:917-26.
22. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995;55:3140-8.
23. Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol 2002;23:61-9.
24. Perera RM, Narita Y, Furnari FB, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005;11:6390-9.
25. Luwor RB, Johns TG, Murone C, et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001;61:5355-61.
26. Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 2002;98:398-408.
27. Reist CJ, Archer GE, Kurpad SN, et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of thetyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 1995;55:4375-82.
28. Wikstrand CJ, McLendon RE, Friedman AH, et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-40.
29. Reist CJ, Batra SK, Pegram CN, et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol 1997;24:639-47.
30. Wikstrand CJ, Reist CJ, Archer GE, et al. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998;4:148-58.
31. Yang W, Barth RF, Wu G, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res 2005;11:341-50.
32. Ciesielski MJ, Kazim AL, Barth RF, et al. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005;54:107-19.
33. Barth RF, Adams DM, Soloway AH, et al. Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal Chem 1991;63:890-3.
34. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998;36:91-102.
35. Yang W, Barth RF, Carpenter DE, et al. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 1996;38:985-92.
36. Rogus RD, Harling OK, Yanch JC. Mixed field dosimetry of epithermal neutron beams for boron neutron capture therapy at the MITR-II research reactor. Med Phys 1994;21:1611-25.
37. Klein JP, Moeschberger ML, Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer; 2003.
38. Madsen RW, Moeschberger ML. Statistical concepts. Englewood Cliffs (NJ): Prentice-Hall; 1986.
39. Thapar K, Rutka JT, Laws ER, Jr. Brain edema, increased intracranial pressure, vascular effects, and other epiphenomena of human brain tumors. Chapter 9. In: Kaye AH, Laws JT, Jr., editors. Brain tumors. Edinburgh: Churchill Livingstone; 1997. p. 163-89.
40. Kleihues P, Burger PC, Plate KH, et al. Glioblastoma. In: Kleihues, P, Cavenee, WK, editors. Tumours of the nervous system pathology & genetics. Lyon (France): IARC; 1997. p. 16-24.
41. Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res 1997;57:1129-36.
42. Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Int J Radiat Oncol Biol Phys 2000;47:209-18.
43. Wu G, Barth RF, Yang W, et al. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anti-Cancer Agents Med Chem 2006;6:167-84.
44. Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997;87:586-94.
45. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8.
46. Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102:267-75.
47. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006;24:115-22.
48. Fenstermaker RA, Capala J, Barth RF, et al. The effect of epidermal growth factor receptor (EGFR) expression on in vivo growth of rat C6 glioma cells. Leukemia 1995:9 Suppl 1:106-12.
49. Yang W, Barth RF, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: functional and neuropathologic effects of blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. J Neurooncol 2000;48:179-90.
50. Prise KM, Belyakov OV, Folkard M, et al. Studies of bystander effects in human fibroblasts using a charged particle microbeam. Int J Radiat Biol 1998;74:793-8.
51. Zhou H, Randers-Pehrson G, Waldren CA, et al. Induction of a bystander mutagenic effect of α particles in mammalian cells. Proc Natl Acad Sci U S A 2000;97:2099-104.
52. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with α-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res 2001;155:288-96.
53. Wang R, Coderre JA. A bystander effect in α-particle irradiations of human prostate tumor cells. Radiat Res 2005;164:711-22.
54. Miyatake S, Kawabata S, Kajimoto Y, et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 2005;103:1000-9.
55. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
56. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005;27:684-94.
57. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
58. Nygren P, Sorbye H, Osterlund P, et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
59. Nakagawa Y, Pooh K, Kobayashi T, et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J Neurooncol 2003;62:87-99.
60. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 2003;62:101-9.
61. Busse PM, Harling OK, Palmer MR, et al. A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neurooncol 2003;62:111-21.
62. Joensuu H, Kankaanranta L, Seppala T, et al. Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. J Neurooncol 2003;62:123-34.
63. Henriksson R, Capala J, H-Stenstam B, et al. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase 2 study evaluating a prolonged high dose of boronphenylalanine (BPA). Radiotherapy and Oncology 2006 (In press).
64. Coderre JA, Hopewell JW, Turcotte JC, et al. Tolerance of normal human brain to boron neutron capture therapy. Appl Radiat Isot 2004;61:1083-7.
65. Ono K, Masunaga S, Suzuki M, et al. The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice. Int J Radiat Oncol Biol Phys 1999;43:431-6.
66. Barth RF, Joensuu H. Boron neutron capture therapy in the treatment of glioblastoma: As effective, more effective or less effective than photon irradiation? Radiotherapy and Oncology 2006 (In press).
67. Vicente MGH. Boron in medicinal chemistry. AntiCancer Agents Med Chem 2006;6:73-181.
68. Wu G, Barth RF, Yang W, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 2006;5:52-9.